Monte Rosa Therapeutics Inc

NASDAQ GLUE

Data sourced from

and

Download Data

Monte Rosa Therapeutics Inc Working Capital To Sales Ratio for the Trailing 12 Months (TTM) ending March 31, 2024: 16.07

Monte Rosa Therapeutics Inc Working Capital To Sales Ratio is 16.07 for the Trailing 12 Months (TTM) ending March 31, 2024. The working capital to sales ratio measures the proportion of working capital to revenue. It is calculated by dividing the difference between current assets and current liabilities by revenue. This ratio provides insights into the efficiency of working capital utilization relative to revenue generation. A higher ratio suggests better utilization of working capital to generate sales revenue.

NASDAQ: GLUE

Monte Rosa Therapeutics Inc

CEO	Dr. Markus Warmuth M.D.
IPO Date	June 24, 2021
Location	United States
Headquarters	645 Summer Street, Boston, MA, United States, 02210
Employees	130
Sector	Healthcare
Industry	Biotechnology

Description

Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops MRT-2359, an orally bioavailable molecular glue degrader targeting the translation termination factor protein GSPT1 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of systemic and central nervous system autoimmune diseases; and MRT-8102 for the treatment of IL-1"/NLRP3 driven inflammatory diseases. It also develops CDK2 to treat ovarian, uterine, and breast cancers. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.

Key trends